Skip to main content

Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis

Abstract

Background

Malignant peritoneal mesothelioma is a rare and often fatal disease. Dissemination is confined to the abdominal and pelvic peritoneal spaces in a great majority of patients.

Methods

Standardized cytoreductive surgery and perioperative chemotherapy was used in all patients. Long-term normothermic intraperitoneal chemotherapy (NIPEC) was added to the treatment of our most recent group of patients. Survival with and without NIPEC was compared using a propensity-matched analysis.

Results

In a uniform group of 74 patients, the clinical- and treatment-related features that had an impact on survival were age (hazard ratio [HR] 1.99, 95% confidence interval [CI] 0.929–4.238, p = 0.0766), completeness of cytoreduction (HR 2.356, 95% CI 1.113–4.989, p = 0.0251), and treatments administered (HR 3.497, 95% CI 1.199–10.20, p = 0.0219). In the Cox proportional hazards multivariant model, sex and age were borderline significant. Treatments administered were significant (HR 3.549, 95% CI 1.157–10.888, p = 0.0268). Using five features to match 29 patients in the control group (no NIPEC) to 29 patients in the experimental group (with NIPEC), the propensity-matched survival was significantly different (p = 0.0263).

Conclusions

The addition of NIPEC was associated with long-term survival in this cohort of patients. A multi-institutional randomized trial may be the next step.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20(6):935–44.

    Article  Google Scholar 

  2. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67(10):999–1003.

    CAS  PubMed  Google Scholar 

  3. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12(3):605–21.

    Article  Google Scholar 

  4. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.

    CAS  Article  Google Scholar 

  5. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–37.

    Article  Google Scholar 

  6. Taub RN, Hesdorffer ME, Keohan ML. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma (MPM). J Clin Oncol. 2005;23:664s.

    Article  Google Scholar 

  7. Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405–12.

    CAS  Article  Google Scholar 

  8. Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31(10):784–8.

    Article  Google Scholar 

  9. Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(9):980–5.

    CAS  Article  Google Scholar 

  10. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17(10):2720–7.

    Article  Google Scholar 

  11. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian Experience. J Surg Oncol. 2009;99:109–13.

    Article  Google Scholar 

  12. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2010;27:6237–42.

    Article  Google Scholar 

  13. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686–93.

    Article  Google Scholar 

  14. Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–35.

    Article  Google Scholar 

  15. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.

    Article  Google Scholar 

  16. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416–24.

    Article  Google Scholar 

  17. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228–35.

    CAS  Article  Google Scholar 

  18. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    CAS  Article  Google Scholar 

  19. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49–58.

    Google Scholar 

  20. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(9):948–53.

    CAS  Article  Google Scholar 

  21. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13(5):635–44.

    Article  Google Scholar 

  22. Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14(2):515–25.

    Article  Google Scholar 

  23. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27–32.

    Article  Google Scholar 

  24. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    CAS  Article  Google Scholar 

  25. Sugarbaker PH, van der Speeten K. An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy. In: Sugarbaker PH (ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd Edition. Woodbury, CT: Cine-Med Publishing; 2017. pp. 17–46.

  26. Van der Speeten K, Stuart OA, Sugarbaker PH. Cancer chemotherapy for peritoneal metastases: Pharmacology and treatment. In: Sugarbaker PH (ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd Edition. Woodbury, CT: Cine-Med Publishing; 2017. pp. 47–82.

  27. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous ifosfamide. Int J Surg Oncol. 2011. https://doi.org/10.1155/2011/185092.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52(5):405–10.

    CAS  Article  Google Scholar 

  29. Sugarbaker PH, Bijelic L. Adjuvant bidirectional chemotherapy using an intraperitoneal port. Gastroenterol Res Pract. 2012;2012:752643.

    PubMed  PubMed Central  Google Scholar 

  30. Sugarbaker PH, Stuart OA. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with intraperitoneal paclitaxel. Surg Oncol. 2020;33:96–9.

    Article  Google Scholar 

  31. Gant T, Crowland K. A practical guide to getting started with propensity scores. Paper 689-2017. Available at: https://support.sas.com/resources/papers/proceedings17/0689-2017.pdf.

  32. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14(1):41–9.

    Article  Google Scholar 

  33. Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;15:839–49.

    Article  Google Scholar 

  34. Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69–79.

    CAS  Article  Google Scholar 

  35. Jänne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1(6):506–12.

    Article  Google Scholar 

  36. Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects focused issue: intraperitoneal chemotherapy for peritoneal metastases: HIPEC, EPIC, NIPEC, PIPAC and more. J Gastrointestinal Oncol. 2020. https://doi.org/10.21037/jgo-2020-3. (in press).

    Article  Google Scholar 

  37. Kuh HJ, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290:871–80.

    CAS  PubMed  Google Scholar 

  38. Sugarbaker PH, Chang D, Jelinek JS. Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma. Eur J Surg Oncol. 2021. https://doi.org/10.1016/j.ejso.2021.04.012. (in press).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul H. Sugarbaker MD, FACS, FRCS.

Ethics declarations

Paul H. Sugarbaker and David Chang have no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sugarbaker, P.H., Chang, D. Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis. Ann Surg Oncol 28, 7109–7117 (2021). https://doi.org/10.1245/s10434-021-10048-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10048-4